| Ranbaxy gets USFDA nod for Macrobid alternate |
| Our Web Bureau / Mumbai April 1, 2005 |
| Ranbaxy Laboratories has received approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Nitrofurantoin Monohydrate/Macrocrystals capsules, 100 mg. According to a Ranbaxy release issued to the BSE, USFDA has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Macrobid |
